Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its First-In-Class Lag-3 Candidate, Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer

Image Source: ©2022 Kalkine Media®

Nov 29 (Reuters) - Immutep Ltd:

* IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, AND AVELUMAB TO TREAT UROTHELIAL CANCER

* IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, AND AVELUMAB TO TREAT UROTHELIAL CANCER

* IMMUTEP LTD - FIRST PATIENT IS EXPECTED TO BE ENROLLED AND DOSED IN H1 OF CALENDAR YEAR 2023

* IMMUTEP LTD - UNDER AGREEMENT, IMMUTEP AND MERCK KGAA, DARMSTADT, GERMANY WILL JOINTLY FUND INSIGHT-005 STUDY Source text for Eikon: Further company coverage:



 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use on